SCHEMBL14063754

SCHEMBL14063754

O=C(N[C@H](CSCC1c2ccccc2-c2ccccc21)C(=O)O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 4/20 0.58
▸ PPARG P37231 2/20 0.58
▸ IDO1 P14902 2/20 0.53
▸ TDO2 P48775 1/20 0.53
▸ SLC17A5 Q9NRA2 1/20 0.50
▸ HDAC1 Q13547 2/20 0.48
▸ HDAC2 Q92769 2/20 0.48
▸ HDAC3 O15379 1/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ HDAC7 Q8WUI4 1/20 0.47
▸ HDAC10 Q969S8 1/20 0.47
▸ HDAC11 Q96DB2 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ HDAC9 Q9UKV0 1/20 0.47
▸ HDAC5 Q9UQL6 1/20 0.47
▸ NCOR2 Q9Y618 1/20 0.47
▸ CASP1 P29466 2/20 0.46
▸ CTSL P07711 2/20 0.45
▸ CTSB P07858 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19888241 0.88 SLC17A5 (0.58) SLC17A5MDM4TP53
SCHEMBL8139788 0.85 CASP1 (0.48) PPARAPPARGSLC17A5CASP1MDM4
SCHEMBL6989365 0.85 CASP1 (0.48) PPARAPPARGSLC17A5CASP1MDM4
SCHEMBL2399667 0.84 SLC17A5 (0.47) PPARAPPARGIDO1TDO2SLC17A5
SCHEMBL12707588 0.84 SLC17A5 (0.47) PPARAPPARGIDO1TDO2SLC17A5
SCHEMBL17446645 0.84 HDAC1 (0.57) PPARAPPARGIDO1TDO2SLC17A5
SCHEMBL23927277 0.84 PPARA (0.73) PPARAPPARGIDO1TDO2HDAC1
SCHEMBL13716720 0.82 SLC17A5 (0.53) PPARAPPARGIDO1TDO2SLC17A5
SCHEMBL12065748 0.82 PPARA (0.60) PPARAPPARGIDO1SLC17A5
SCHEMBL29908094 0.82 SLC17A5 (0.61) PPARAPPARGSLC17A5MDM4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7420051-B2 Antitumor agents; microbiocides; antibiotics; forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxyl, di-6,8-en-5-one fused ring compound. After formation of the 1,4 brige, C-18 protection is removed before spiroamine introduction PHARMA MAR, S.A. (ES) 2008-09-02 — — US disclosed
Send feedback